Tag Archive for: The Michael J. Fox Foundation

Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders

/in

New prestigious grants support Lario’s unique portfolio of calcium channel programmes Indication expansion into Parkinson’s disease, and PTSD (post-traumatic stress disorders) Builds on prior support from The Michael J. Fox Foundation and further validates Lario’s precision neuroscience platform Edinburgh, UK – 19 February 2026 – Lario Therapeutics (“Lario” or the “Company”), a biopharmaceutical company developing […]

Read more

Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation

/in

Cambridge, UK, 06 June 2024 – Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces that it has been awarded a grant of US$595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program. The grant will fund research performed at […]

Read more

Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease

/in

Copenhagen, Denmark, 23rd January 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the Company has been awarded a grant (MJFF-024128) worth c.US$873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease. The […]

Read more

Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies

/in

Lausanne, SWITZERLAND and San Francisco, CA, USA, 4 May 2022 – Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today announces that it has been awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the study of its clinical stage O-GlcNAcase (OGA) […]

Read more